The Oncology Institute, Inc. (TOI)
| Previous Close | 0.8835 |
| Open | 0.8900 |
| Bid | 0.8827 x 100 |
| Ask | 0.9773 x 100 |
| Day's Range | 0.8900 - 0.9995 |
| 52 Week Range | 0.3300 - 2.6550 |
| Volume | |
| Avg. Volume | 122,442 |
| Market Cap | 69.847M |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9200 |
| Earnings Date | May 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireThe Oncology Institute to Participate in Panel Discussion at the Leerink Healthcare Transformation Summit
CERRITOS, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology practices in the country, today announced that Dr. Daniel Virnich, TOI’s Chief Executive Officer, will participate in the “Defining the Next Chapter in Value-Based Care” panel at the Leerink Healthcare Transformation Summit in Montecito at 8:30am ET on May 16, 2024. About The Oncology Institute, Inc. Founded in 2007, The Oncology Institute, Inc. and its affiliate
- GlobeNewswire
The Oncology Institute Announces First Quarter 2024 Earnings Release Date and Conference Call
CERRITOS, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2024 financial results after the market close on Tuesday, May 14, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-
- GlobeNewswire
Jordan McInerney Appointed as Chief Development Officer of The Oncology Institute
Executive Brings Wealth of Experience in Advancing Value-Based Specialty Care Models CERRITOS, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) is pleased to announce the appointment of Jordan McInerney as the new Chief Development Officer (CDO), effective April 1, 2024. In this role, Mr. McInerney will spearhead growth initiatives for The Oncology Institute across diverse markets, including cultivating new partnerships with payors, driving
